Stoke Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2018 | $-11.0M | $-11.9M | $935.0K | $240.0K |
| FY2019 | $-31.1M | $-32.7M | $1.6M | $1.9M |
| FY2020 | $-42.2M | $-43.3M | $1.1M | $5.8M |
| FY2021 | $-66.9M | $-68.1M | $1.2M | $16.5M |
| FY2022 | $-31.9M | $-35.8M | $4.0M | $22.9M |
| FY2023 | $-81.1M | $-82.7M | $1.6M | $25.3M |
| FY2024 | $-86.9M | $-87.1M | $203.0K | $27.5M |
| FY2025 | $45.6M | $44.9M | $670.0K | $32.2M |